Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
|Articles|September 16, 2008
- March31 2004
- Volume 11
- Issue 6
Home Appraisal Pressure
Advertisement
How much is the house you want tobuy really worth? Most mortgage lendershire a house appraiser to crunch the numbers,but a recent study by OctoberResearch reveals that more than half ofall appraisers feel pressured by lenders toinflate the value of the homes they lookat. According to the report, 55% ofappraisers surveyed say that they have feltsuch pressure and more than a quarter ofthem say it happens in more than half ofthe cases they handle. Mortgage lenders,who have been feeling the squeeze from adrop in refinancings, may use the highervaluations to collect the larger fees thatcome with bigger loans.
Articles in this issue
about 18 years ago
Consider the Tax Aftermath of Inheritanceabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Should You Have Malpractice Coverage?about 18 years ago
Have Liability on Your Side in Protestsabout 18 years ago
Avoid the Confusion of Tax Law Changesabout 18 years ago
Clear Out the Contents of Your Walletabout 18 years ago
Cruise the River of Kings in Bangkokabout 18 years ago
Cinema Consults: Real Women Have Curvesabout 18 years ago
A Patient with Real "Passion" for Lifeabout 18 years ago
Liability TroublesAdvertisement
Related to this article
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy
5